Previous 10 | Next 10 |
Celldex (CLDX): Q4 GAAP EPS of -$0.55 misses by $0.18.Revenue of $3.79M (+325.8% Y/Y) beats by $3.19M.Cash, cash equivalents and marketable securities of $194.4M.Press Release For further details see: Celldex EPS misses by $0.18, beats on revenue
HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020. “Celldex made significant progress across our pipeline in 2020 and today continue...
Gainers: Humanigen (HGEN) +81%.Universe Pharmaceuticals (UPC) +70%.SeaChange International (SEAC) +60%.Elite Education Group International (EEIQ) +34%.Cyanotech (CYAN) +34%.Fly Leasing (FLY) +27%.Trinity Biotech (TRIB) +25%.Virpax Pharmaceuticals (VRPX) +21%.Hall of Fame Resort & Ent...
Shares of Celldex Therapeutics (NASDAQ: CLDX) were tanking 34.1% as of 11:56 a.m. EDT on Monday. The big decline came after Celldex announced interim results from a phase 1b study of CDX-0159 in treating patients with chronic inducible urticaria (CIndU), severe hives that affect aro...
Celldex Therapeutics (CLDX) reports interim data from its Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU) and symptomatic dermographism ((SD)), the two most common forms of chronic inducible urticaria (CIndU), a disturbing allergic...
--CDX-0159 generally well tolerated to date-- --Conference call to be held at 7:45 a.m. ET today-- HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported interim data from the Company’s ongoing, open label...
HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company’s participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The presentation for the virtual conference was prerecorded and will be ac...
--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation-- --Potential to expand future CDX-0159 development beyond chronic urticarias to chronic pruritic d...
HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. ET. A webcast of the ...
Healthcare lagged the broader market last year, but that can change this year. A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare. Best positioned are industry groups within healthcare that can achieve secular growth beyond the cyclical rise. Biot...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...